Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Ethylestrenol is a synthetic androgen and anabolic steroid (AAS) that was formerly used in humans to promote weight gain and treat conditions such as anemia and osteoporosis, but has since been discontinued for human use. It remains available for veterinary purposes in some countries. The drug acts primarily as an agonist of the androgen receptor, exhibiting strong anabolic effects relative to its weak androgenic activity, and also possesses significant progestogenic properties. Ethylestrenol is a 17α‐ethylated derivative of nandrolone and functions as a prodrug of norethandrolone. Its mechanism involves binding to the androgen receptor, modulating gene expression related to cellular proliferation and differentiation. Side effects include masculinization symptoms and risk of liver toxicity due to its 17α‐alkylation[3][5][6].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on ethylestrenol.